Akademik Veri Yönetim Sistemi
International Multidisciplinary Symposium on Drug Research and Development (DRD 2023), İzmir, Türkiye, 4 - 06 Mayıs 2023, ss.1
Sertraline is one of the selective serotonin reuptake inhibitors indicated in major depressive disorder (1). Schizophrenia is a mental disorder with frequent depressive symptoms. Sertraline is thought to be useful for the treatment of depressive symptoms in schizophrenia (2). The aim of this study is to develop nanofiber strips containing sertraline which can be easily dispersed by the buccal route, suitable for the use of schizophrenia patients. In this study, sertraline-containing nanofibers were prepared using the electrospinning method. The reason for choosing the electrospinning method is the high wettability and porosity of the prepared nanofibers, hence easily dispersible strips can be prepared (3).
Here, various ratios (%5, %7.5 and %10) of polyvinyl pyrrolidone (PVP) polymer solutions were prepared, and electrical conductivity, viscosity and surface tension characterization studies were performed on polymer solutions. After characterization studies, a polymer solution containing 5% PVP was selected to prepare nanofibers. The surface tension and conductivity of the polymer solution were measured as 25.95±0.31 mN/m and 13.12±1.86 µS/cm, respectively. Nanofibers were obtained by using the electrospinning method, each strip (3x2 cm in size) containing 5 mg sertraline. The mechanical properties of nanofibers were investigated. Furthermore, in vitro release study was performed on Franz diffusion cells using a dialysis membrane. The permeability coefficient and flux of the sertraline from nanofibers were 0.0065±0.0007 and 20.66±2.17, respectively. As a result of the drug release study, more drug release was observed from the nanofiber compared to the polymer solution and plain sertraline solution. (Figure 1). In this study, electrospun nanofibers containing sertraline were successfully obtained. The results showed that sertraline nanofiber strips can be used to treat symptoms of schizophrenia.